Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028

By Reuters News

Oct 15 (Reuters) - Crescent Biopharma, Inc. CBIO.O:

  • CRESCENT BIOPHARMA - POTENTIAL TO INITIATE FIRST CR-001 PHASE 3 STUDY IN EARLY 2028

  • CRESCENT BIOPHARMA - MULTIPLE SAC-TMT PLUS CR-001 PHASE 2 STUDIES ONGOING IN OVER 700 PATIENTS; DATA MID-2027

  • CRESCENT BIOPHARMA -ON TRACK TO REPORT INITIAL MONOTHERAPY DATA FROM ASCEND IN Q1 2027, INCLUDING ANTITUMOR RESPONSE FOR FIRST-LINE NSCLC COHORT

  • CRESCENT BIOPHARMA - APOLLO PHASE 1/2 TRIAL OF CR-002 TO COMMENCE DOSING THIS QUARTER; DATA H2 2027

  • CRESCENT BIOPHARMA - PHASE 1/2 TRIAL OF CR-003 ONGOING IN CHINA; INITIAL DATA EXPECTED Q1 2027

Further company coverage: CBIO.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.